Fayez Sarofim & Co. held its stake in DaVita HealthCare Partners Inc. (NYSE:DVA) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,100 shares of the company’s stock at the end of the second quarter. Fayez Sarofim & Co.’s holdings in DaVita HealthCare Partners were worth $525,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in DVA. SRS Capital Advisors Inc. lifted its position in DaVita HealthCare Partners by 6.6% during the first quarter. SRS Capital Advisors Inc. now owns 1,966 shares of the company’s stock valued at $133,000 after buying an additional 122 shares in the last quarter. Pzena Investment Management LLC lifted its position in DaVita HealthCare Partners by 2.1% during the second quarter. Pzena Investment Management LLC now owns 3,398 shares of the company’s stock valued at $220,000 after buying an additional 71 shares in the last quarter. Pacer Advisors Inc. lifted its position in DaVita HealthCare Partners by 3.0% during the first quarter. Pacer Advisors Inc. now owns 3,422 shares of the company’s stock valued at $233,000 after buying an additional 101 shares in the last quarter. LMR Partners LLP acquired a new position in DaVita HealthCare Partners during the first quarter valued at approximately $242,000. Finally, Elk Creek Partners LLC lifted its position in DaVita HealthCare Partners by 13.5% during the first quarter. Elk Creek Partners LLC now owns 3,885 shares of the company’s stock valued at $264,000 after buying an additional 463 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/19/fayez-sarofim-co-continues-to-hold-position-in-davita-healthcare-partners-inc-dva.html.

DaVita HealthCare Partners Inc. (NYSE DVA) traded down 0.96% on Tuesday, hitting $60.13. 273,525 shares of the stock were exchanged. DaVita HealthCare Partners Inc. has a one year low of $54.50 and a one year high of $70.16. The company has a market cap of $11.50 billion, a P/E ratio of 9.16 and a beta of 0.91. The company’s 50 day moving average price is $58.10 and its 200-day moving average price is $64.19.

DaVita HealthCare Partners (NYSE:DVA) last announced its earnings results on Tuesday, August 1st. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.02. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.82 billion. DaVita HealthCare Partners had a return on equity of 14.02% and a net margin of 8.68%. The company’s revenue was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.01 earnings per share. Equities research analysts predict that DaVita HealthCare Partners Inc. will post $3.59 EPS for the current fiscal year.

DVA has been the topic of a number of recent research reports. Jefferies Group LLC set a $70.00 price target on shares of DaVita HealthCare Partners and gave the company a “buy” rating in a research report on Friday, May 26th. TheStreet cut shares of DaVita HealthCare Partners from a “b” rating to a “c+” rating in a research report on Wednesday, August 2nd. Royal Bank Of Canada reaffirmed a “hold” rating and set a $64.00 price target on shares of DaVita HealthCare Partners in a research report on Wednesday, September 6th. Zacks Investment Research raised shares of DaVita HealthCare Partners from a “sell” rating to a “hold” rating in a research report on Thursday, August 3rd. Finally, BidaskClub cut shares of DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research report on Saturday, July 8th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $68.88.

DaVita HealthCare Partners Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Institutional Ownership by Quarter for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Stock Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related stocks with our FREE daily email newsletter.